Back to search results
NCT05744713

An Observational Study of Patients With Chronic Liver Disease

Enrolling by Invitation
Not specifiedAges 18+Observational
Target PharmaSolutions, Inc.
~500,000 participants
Updated 2026-03-03 on ClinicalTrials.gov
What's tested:Observational

At a glance

Recruiting sites
0 of 10 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To characterize the natural history of disease in patients with CLD from various etiologies and Cirrhosis
Measured over 20 Years
+2 more outcomes measured

Conditions

Chronic Liver Disease
Cirrhosis

Explore related trials

Chronic Liver DiseaseCirrhosis

NCT05744713

Where you'd take part

This study runs at 10 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Atrium Health Center for Liver Disease and Transplant

    Charlotte, North Carolinano site contact published

  • Baylor College of Medicine

    Houston, Texasno site contact published

  • Baylor Scott & White Research Institute

    Dallas, Texasno site contact published

  • Columbia University Irving Medical Center/ New York Presbyterian Hospital

    New York, New Yorkno site contact published

  • Georgetown Medstar Transplant Institute

    Washington D.C., District of Columbiano site contact published

  • Keck School of Medicine of USC

    Los Angeles, Californiano site contact published

  • Rush University Medical Center

    Chicago, Illinoisno site contact published

  • Stanford Medicine

    Redwood City, Californiano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adult\* patients diagnosed and managed for CLD/cirrhosis invited to participate
Ability to provide written informed consent

Exclusion

Death
Manual removal (sponsor or site request)
No EHR interface encounter \> 3 years.
Patient expressed desire to withdraw consent to complete PROs
Failure to complete PROs within 24 weeks of initial invitation
Greater than 24 months lapse of survey completion after baseline surveys completed
Additionally, the criteria detailed for Disease Cohort apply to the Engaged Cohort.

What this trial measures

  • To characterize the natural history of disease in patients with CLD from various etiologies and Cirrhosis20 Years
  • To assess safety and effectiveness of CLD/Cirrhosis treatments and treatments for complications of any chronic liver disease20 Years
  • To establish learning health networks focused on quality of care for patients20 Years